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Abstract 
The prognosis and clinical management of chronic liver diseases are highly dependent on the extent of liver fibrosis. Bigger the 
fibrosis, worse the prognosis; and bigger the risk of progression to cirrhosis.  In current practice, liver biopsy is most frequently 
performed to assess the grade of inflammation and stage of fibrosis thereby providing prognostic information on which to base 
treatment decisions upon.  
Liver biopsy is becoming more and more useless in the management of chronic liver disease due to large sampling error, 
consistent inter-observer disagreement, high emotional cost of patient, enormous health care commitment in case of rare but 
possible severe complications, the fact that it is a snapshot of a process that is everything but a frozen one. Therefore, every 
methodology that avoids performing this invasive procedure is welcome. 
The purpose of this article is to present the noninvasive evaluation of patients with chronic liver disease as an alternative of liver 
biopsy in the assessment of hepatic structure and function. 
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Hepatic fibrosis and cirrhosis are the endpoints of 
most types of chronic liver disease and the result of 
replacement of liver tissue with collagenous scar. The 
liver responds to injury with wound healing and, 
subsequently, fibrosis. This response occurs after 
essentially all kinds of injury (e.g. from virus, alcohol, iron, 
copper). Fibrosis is a result of an imbalance between 
fibrolytic and fibrogenic processes.  Hepatic stellate cells 
(HCSs) are the key effector of cell fibrogenesis. In the 
normal liver HCSs are quiescent, but with liver injury they 
are activated and transform into myofibroblast-like cells, 
capable of proliferation. In addition, HSCs are an 
important source of metalloproteinase (TIMPs), matrix-
degrading proteases with a central role in the remodeling 
of extracellular matrix. 
Progressive scarring in response to a persisting liver 
insult leads to “cirrhosis” characterized by fibrotic bands, 
parenchymal nodules and vascular distortion. Hepatic 
fibrosis and cirrhosis are morphologically defined and the 
pattern and extent of the morphological changes depend 
on the cause and stage of fibrosis. Accordingly, there is a 
wide spectrum in the degree of fibrosis and in the severity 
of clinical symptoms. Clinical presentation may vary 
widely, ranging from absent or nonspecific symptoms to 
life threatening ones. In most cases, no clear dividing line 
can be drawn between cirrhosis and the preceding liver 
disease because the transition is gradual and unapparent. 
Indications for assessing liver fibrosis 
It is important to have a safe and effective diagnostic 
tool for liver fibrosis for several reasons. Firstly, fibrosis is 
a central parameter of the severity of chronic liver disease 
associated with liver morbidity and mortality. Secondly, 
fibrosis is a key predictor for further progression to 
cirrhosis. Thirdly, advanced stage of fibrosis is the major 
criterion to start causal treatment.  
For years, liver fibrosis was considered irreversible; 
however, there is accumulated clinical and experimental 
evidence to suggest that this axiom should be rejected. 
Reversal of fibrosis is a reality in some cases. Existing 
treatments, particularly those that treat the primary injury, 
can allow the complete resolution. When the underlying 
insult can be removed, it may soon be possible to offer 
patients specific antifibrotic therapy to reverse liver 
damage.  
Assessing liver fibrosis is relevant for validation and 
monitoring any antifibrotic therapy. If compared to other 
prognostic parameters, fibrosis is definitely more 
important than liver inflammation and liver steatosis. 
Options for Liver fibrosis assessment 
Percutaneous Liver biopsy              
Limitations of liver biopsy 
Although liver biopsy is often called the gold standard 
for assessment of liver disease, the true standard is the Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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clinical outcome or what happens to the patient. Liver 
biopsy was initially developed as a diagnostic tool to help 
determine the cause of liver dysfunction. In some 
instances, liver biopsy is performed to determine the 
effect of treatment of known liver disease. It is an invasive 
procedure with certain unavoidable risks and 
complications. Significant complications occur in 1-5% of 
patients and the mortality rate is reported to be 1:1000 
and 1/10.000 (Table 1). Despite these reservations, 
needle liver biopsy remains the primary tool in diagnosing 
liver diseases and in staging liver fibrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Uncooperative patient 
Bleeding disorder 
Infection of skin, pleura, right lower lung or peritoneum 
overlying the liver 
Suspected liver abscess or vascular lesion 
Difficulty in determining liver location, as with ascites 
Severe extrahepatic obstruction 
 
Needle liver biopsy, however, removes only about 
1/50.000 of the liver and so carries substantial sampling 
error. Both autopsy and laparoscopic studies have clearly 
shown that cirrhosis is missed on a single blind liver 
biopsy in 10-30% of cases. Both the size of the biopsy 
and the number of biopsies taken have a major effect on 
accuracy. An adequate biopsy should be at least 15 mm 
in length and contain more than 5 portal tracts. Studies 
have shown that biopsy specimens less than 25 mm in 
length can lead to underdiagnosis of cirrhosis; therefore, 
some investigators recommend larger biopsies. The 
problem of sampling error is compounded because liver 
biopsies are more and more often performed using the 
transjugular or radiographically guided approach, by 
which smaller samples are obtained. 
Several studies have investigated the inter-observer 
and intra-observer variability in the histological and 
pathologic diagnosis of liver fibrosis based on biopsy 
specimens. Staging scores for fibrosis such as METAVIR, 
Ishak and Scheuer systems were created to standardize 
the evaluation of liver biopsies to minimize observer 
variation. Although not as great as the errors attributed to 
sampling variability, errors in disease staging for fibrosis 
with a 1 METAVIR stage appear occur in up to 20% of 
patients and a misdiagnosis of cirrhosis in 15% of 
patients. Staging errors especially for therapeutic 
decisions can lead to under treatment. This is particularly 
true for METAVIR stage 2 patients with chronic hepatitis 
C. Considering non-invasive tests, it is important to realize 
that the comparator liver biopsy is wrong in 20 % of 
cases, particularly where there is intermediate stage 
disease.  More problems with histology are: 
•  fibrosis progression in the majority of patients is 
slow, from normal to cirrhosis (stage 0 to stage 4 
in >20 years). 
•  follow-up biopsy is too insensitive to detect 
changes in fibrosis progression or regression 
within weeks to months or even years. 
To quantify fibrosis more accurately, automated 
morphometry was investigated. Although the quantity of 
fibrosis detected with morphometry correlates to the 
stages of fibrosis, the nature of this relationship is not 
linear. As technology continues to develop, incorporation 
of topography and quantification of fibrosis may increase 
the value of this automated technology. 
 
Noninvasive Tests 
Noninvasive tests are an attractive alternative to 
hepatic biopsy in standardizing and monitoring chronic 
liver affections. This is the reason why the efforts to 
assess the lesions stage through non-invasive methods 
are justified. A noninvasive method which can provide the 
same information is also desired in the cases in which this 
technique cannot be possible. In a conventional way, 
lesion degree is assessed through tests that reflect the 
hepatic cells’ permeability (transaminases) and the 
activity of hepatic cells synthesis (albumin, bilirubin, 
protrombin time). Noninvasive tests can be classified in 
several ways based on the modality of the test (serum 
blood tests or imaging) or the constituents of the tests 
(direct markers versus indirect markers of fibrosis). With 
the evolution of noninvasive tests, the performance can 
improve particularly with the use of combination or serial 
noninvasive tests.  
 
 Serological assays 
A large number of serological markers of liver hepatic 
fibrosis have been studied for their accuracy in staging 
hepatic fibrosis. The ideal fibrosis test would have a high 
sensitivity and specificity, be relatively inexpensive, reflect 
fibrosis irrespective of cause and be easy to perform 
being reproducible and easily interpreted.  
 
Direct serum markers of liver fibrosis  
It has been suggested that measurement of direct 
serum markers of fibrogenesis, such as procollagen type 
III N-terminal peptide (PIIINP) and direct serum marker of 
Fig.1 Percutaneous Liver Biopsy (Menghini)
 Table 1 Contraindications to percutaneous Liver Biopsy Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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fibrolysis (MMP-1) might be helpful in evaluating liver 
fibrosis. Because of the lack of specificity, no marker of 
liver fibrosis has demonstrated test characteristics 
equivalent to liver biopsy.       
 
 
 
 
 
 
 
 
 
 
 
Indirect markers of liver fibrosis. 
A variety of indirect markers of liver fibrosis have 
been evaluated. Several simple ratios and indices have 
been developed using aminotransferases, platelet count, 
prothrombine time and age, such as the aspartate 
aminotransferase (AST)/alanine aminotransferase (ALT) 
ratio, the age-platelet index (AP index), the Pohl score, 
the cirrhosis determinant score (CDS) and the AST to 
platelet ratio index (APRI). Multivariate analyses have 
been directed at identifying markers of fibrosis among 
extracellular matrix molecules for combination into 
multicomponent serum panel or models with more testing 
capabilities. The most widely known of these are listed in 
 
 
 
 
   
FPI                    Age, cholesterol, insulin resistance, past alcohol use,   AST          
Pohl Score        Platelet, AST, ALT          
Fibrotest           α 2 macroglobulin, GGT, age, sex, haptoglobin, total bilirubin, apolipolipoptrtein A1 
Forns Index      Age, platelet, GGT, cholesterol 
APRI Index     AST, platelet 
Hepa Score       Age, sex, hyaluronic acid, α 2 macroglobulin, GGT 
ELF                   Propeptide III collagen, haptoglobin, TIMP-1 
ELFGA             Age, amino-terminal propeptide of type III collagen, haptoglobin, TIMP-1 
FibroSpect II    Haptoglobin, TIMP-1, α 2 macroglobulin 
Table 2 Serum indices of hepatic fibrosis 
 
 
The results of all these tests are similar to ROC that 
show an area under the curve (AUC) of approximately 
0,80-0,85. The clinical utility of these tests is to rapidly 
screen patients for the presence of mild or significant liver 
disease. They can prevent the need for liver biopsy in 
40% of patients and can be followed up over time. 
Compared with liver biopsy current serum  
 
biomarkers: 
•  rather represent the whole liver; 
•  only permit crude staging; 
•  rather reflect liver function (secretion, endothelial 
uptake). 
The results the serological tests are shown in Table 3 
(adapted from Lai and Afdhal).  
 
 
 
  Patients  Serum Markers  AUROC (95%CI)  Sens.  Spec.  PPV  NPV 
Wai et all  192  APRI  0,88 41%  95%  88%  64% 
Rosenberg et all  1021  ELF  0,80 90,5%  41%  99%  92% 
Imbert-Bismut   339  Fibrotest  0,87 87%  59%  63%  85% 
Castera et all  183  Fibrotest  0,88  NA NA NA NA 
Patel et all  402  Fibrospect  0,831 77%  73%  74%  76% 
Adams et all  221  Hepascore  0,82 63%  89%  88%  95% 
Table 3 Serological Tests for Liver Fibrosis 
 
 
Future studies will focus on using these tests for prediction of clinical outcomes and for the risk of disease 
progression.     
Fig.2 Serum markers  
of fibrosis 
Abbreviations: TIMP-1, tissue inhibitor of metalloproteinase, GGT, γ -glutamine transferase, ELFGA, European Liver Fibrosis 
Group algorithm, AST, aspartate aminotransferase, ALT, alanine aminotransferase 
Abbreviations: PPV, positive predictive value, NPV, negative predictive value. Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Elastography 
Transient elastography is more sensitive than 
currently available radiologic techniques for staging 
hepatic fibrosis. This technique uses a probe, (Fibroscan, 
Echosens), which includes an ultrasonic transducer, that 
creates a vibration of low frequency (50MHz) and 
amplitude, which is transmitted into the liver. The vibration 
wave induces an elastic shear wave that propagates 
through the liver. The velocity of the wave, as it passes 
through the liver, correlates directly with tissue stiffness or 
elasticity; the propagated wave travels faster with 
increasing fibrosis. A pulse-echo ultrasound allows 
measurement of the wave velocity and the results are 
presented as kilopascals (kPa). Stiffness is measured 
within a cylinder, measuring 1 cm in width and 4 cm in 
length, producing an estimated sampling area that is 100 
times greater than biopsy. (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
The elasticity result is given as the median of 10 
accurate measurements; results range from 10 to 90 kPa 
in various stages of chronic liver disease. This technology 
demonstrates many features desirable for the non- 
 
invasive assessment of hepatic fibrosis. It is painless, 
quick (5 min), safe, can be performed bedside. A major 
advantage of transient elastography is the ability to take 
multiple measurements in the same liver. It provides 
immediate results and only short training is necessary. 
The theoretical limitation of transient elastography 
are primarily mechanical factors that produce poor 
propagation of the wave, including the thickness and type 
of tissue separating the liver from the transducer (marked 
obesity and ascites), the “window” quality (the rib space 
may be too narrow to allow good wave propagation) and 
some hepatic tissue characteristics, such as fatty liver or 
liver inflammation. 
Ziol and collegues enrolled 327 patients with chronic 
hepatitis C in a multicenter study comparing METAVIR 
liver fibrosis stages on biopsy specimens with transient 
elastography. It is the largest study of hepatic 
elastography reported which concluded that elastography 
is a reliable tool to detect significant fibrosis or cirrhosis. 
Castera and collegues studied 183 consecutive 
patients who had hepatitis C and compared the results of 
Fibroscan with FibroTest and the aspartate transaminase 
to platelet ratio (APRI) in their ability to detect cirrhosis. 
The investigators concluded that the tests had similar 
value in detecting cirrhosis, although the Fibroscan had 
the single best performance. The authors conclude that 
liver biopsy could be avoided in most patients with 
hepatitis C. 
Another study, by Foucher et all., was carried out 
on 711 patients with chronic liver disease from all 
etiologies. Of the 711 patients, 354 patients had a liver 
biopsy. Foucher et all, found transient elastography to be 
of value in predicting fibrosis; it also correlates with 
complications of cirrhosis such as esophageal varices and 
bleeding, ascites and hepatocellular carcinoma. The 
results of many of these studies are shown in Table 4. 
 
 
 
 
Study  Disease  Prevalence of sign of fibrosis  AUC  Threshold 
kPa 
Sensitivity Specificity 
Fraquelli et al  Mixed  50  0,86  7,6  81%  76% 
Gomez-Dominiguez Mixed  82  0,74  4,0  94%  33% 
Chang et al.  Mixed  44  0,86  9,0  83%  85% 
Castera et al.  HCV  74  0,83  7,1  67%  89% 
Ziol et al.  HCV  65  0,79  8,8  56%  91% 
Yoneda et al.  NAFLD  49  0,87  6,6  83%  81% 
Table 4  Performance of transient elastography 
 
 
An alternative technique is to use MR elastography 
which has the advantage of being able to examine more 
parts of the liver including both lobes although it is 
significantly more expensive and time consuming. 
Future Trends 
Proteomics, genomics, genetic risk profiling and 
breath tests are exciting new technologies under 
Fig. 3. Fibroscan “The stiffer the liver, the faster the shear 
wave propagates” 
Abbreviations: HCV, hepatitis C virus, NAFLD, nonalcoholic fatty liver disease, signf., significant Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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investigation. Incorporation of non-invasive tests into large 
natural history cohort studies and into therapeutic trials 
should be a priority in the next years. 
Conclusions 
•  Advanced fibrosis is the major predictor of 
morbidity and mortality of chronic liver disease. 
•  Sampling variability limits the usefulness of liver 
biopsy to stage fibrosis. 
•  Current biomarkers scores can spare up to 40% 
of patients with F0-F1 liver biopsy. 
•  Clinical proof and monitoring the antifibrotic drug 
effects require better noninvasive tests for 
fibrosis and especially for the dynamics of 
fibrogenesis. 
•  Transient elastography is a very promising 
noninvasive method for the diagnosis of 
significant fibrosis in patients with chronic liver 
disease. 
•  Combining transient elastography with serum 
markers (FibroTest) as first line assessment 
could avoid liver biopsy in the majority of these 
patients. 
•  Transient elastography is currently the most 
accurate method for the diagnosis of cirrhosis. 
•  Because of its excellent acceptance by patients, 
transient elastography could be useful for 
monitoring fibrosis. 
•  Guidelines are needed for its use in clinical 
practice. 
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